REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report)’s share price dropped 7% during mid-day trading on Wednesday . The stock traded as low as $14.19 and last traded at $14.20. Approximately 146,945 shares were traded during trading, a decline of 80% from the average daily volume of 726,679 shares. The stock had previously closed at $15.27. […]
Regenxbio Inc RGNX released Tuesday, Jan. 16, interim data from the Phase 2 AAVIATE trial of ABBV-RGX-314 for wet age-related macular degeneration (wet AMD)…
A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustaining vision health.
Regenxbio (RGNX) Announces Positive Interim Data from Phase II AAVIATE Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.